XTX301 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 358 (planned)
- Started
- May 11, 2023
- Main results expected
- Sep 2028
- Fully finished
- Sep 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)
Measured over: From the first dose of the study drug at Cycle 1 Day 1 up to next applicable cycle visit (Cycle 2 Day 1 or Cycle 3 Day 1). Approximately 21 to 42 days. Each cycle is 21 days.
Incidence of treatment-emergent adverse events (TEAEs) and changes in clinical laboratory values
Measured over: Up to 24 months
Investigator-assessed objective response rate (ORR) per RECIST 1.1 (for all Phase 2 disease specific cohorts except CRPC/APMR-PC)
Measured over: up to 24 months
PSA50 response rate and Investigator-assessed ORR per RECIST 1.1 by CT/MRI for patients with measurable disease (for Phase 2 CRPC/APMR-PC cohort only)
Measured over: up to 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05684965 · record last updated 2026-06-23 · checked 2026-11-09 15:47 UTC